| DC73439 |
Merigolix
|
Merigolix is a potent, selective gonadotrophin releasing hormone (GnRH) antagonist. |
| DC72331 |
Acyline
|
Acyline , a GnRH peptide analogue, is a GnRH antagonist that inhibits gonadotropin and testosterone (T) levels. |
| DC72193 |
Teverelix
|
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer. |
| DC72192 |
Ozarelix
|
Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer. |
| DC70437 |
GnRH antagonist 2
|
GnRH antagonist 2 is a GnRH receptor antagonist that can be used for endometriosis research. |
| DC49638 |
BAY 1214784
|
BAY 1214784 is a potent, selective, and orally active antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R). BAY 1214784 is a spiroindoline derivative compound. BAY 1214784 effectively lowers plasma luteinizing hormone levels by up to 49%, at the same time being associated with low pharmacokinetic variability and good tolerability. BAY 1214784 has the potential for the research of uterine fibroids. |
